Drugmaker Eli Lilly says its COVID-19 antibody drug helped prevent illness among residents and staff of nursing homes and other long-term care locations.
It’s the first major study to show an antibody medication may prevent disease. The drugmaker says residents and staff who got the drug had up to a 57% lower risk of getting COVID-19. Among nursing home residents only, there was up to an 80% reduction in risk.
US regulators last year allowed emergency use of the antibody treatment for mild or moderate COVID-19 cases that don’t require hospitalization. It’s a one-time dose given through an IV.
The study, conducted by the National Institutes of Health, involved more than 1,000 residents and staff at nursing homes and other long-term care locations.
In the US, those residents account for less than 1% of the population, but nearly 40% of deaths from COVID-19. The U.S. leads the world with more than 406,000 deaths.
I'm proud to work at The Times of Israel
I’ll tell you the truth: Life here in Israel isn’t always easy. But it's full of beauty and meaning.
I'm proud to work at The Times of Israel alongside colleagues who pour their hearts into their work day in, day out, to capture the complexity of this extraordinary place.
I believe our reporting sets an important tone of honesty and decency that's essential to understand what's really happening in Israel. It takes a lot of time, commitment and hard work from our team to get this right.
Your support, through membership in The Times of Israel Community, enables us to continue our work. Would you join our Community today?
Thank you,
Sarah Tuttle Singer, New Media Editor
Join the Times of Israel Community
Join Our Community
Already a member? Sign in to stop seeing this
You’re serious. We appreciate that!
We’re really pleased that you’ve read X Times of Israel articles in the past month.
That’s why we come to work every day - to provide discerning readers like you with must-read coverage of Israel and the Jewish world.
So now we have a request. Unlike other news outlets, we haven’t put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.
For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.
Join Our Community
Join Our Community
Already a member? Sign in to stop seeing this
comments